Successful Treatment with Low-dose Crizotinib in a Patient with ROS1-rearranged Lung Cancer Who Developed Crizotinib-induced Heart Failure

Takahiko Hashimoto; Kosuke Takahashi; Sachiko Ota; Nobumasa Okumura; Haruka Kondo; Asuki Fukatsu; Toru Hara

doi:10.2169/internalmedicine.9157-21

CASE REPORTS

Successful Treatment with Low-dose Crizotinib in a Patient with ROS1-rearranged Lung Cancer Who Developed Crizotinib-induced Heart Failure

Takahiko Hashimoto, Kosuke Takahashi, Sachiko Ota, Nobumasa Okumura, Haruka Kondo, Asuki Fukatsu, Toru Hara

Author information

Keywords: ROS1-rearrangement, crizotinib, cardiotoxicity, heart failure, QTc prolongation

JOURNAL OPEN ACCESS

2023 Volume 62 Issue 2 Pages 281-284

DOI https://doi.org/10.2169/internalmedicine.9157-21

Browse “Advance online publication” version

Details

Abstract

Crizotinib shows antitumor activity against C-ros oncogene 1-rearranged non-small-cell lung cancer (NSCLC). While corrected QT interval (QTc) prolongation and bradycardia are known as cardiac adverse effects, little is known about crizotinib-related heart failure. Our patient with C-ros oncogene 1-rearranged NSCLC on a reduced dose of crizotinib (200 mg twice daily) after initially experiencing bradycardia and QTc prolongation developed crizotinib-induced heart failure. With further dose reduction (250 mg once daily), there was no recurrence of any cardiac adverse effects, and the patient achieved a long-term response. Although crizotinib can cause heart failure, continuation of crizotinib at a low dose may be an effective treatment option.

Corresponding author

Register with J-STAGE for free!